Significantly Improving the Bioefficacy for Rheumatoid Arthritis with Supramolecular Nanoformulations

• DOI: 10.1002/adma.202100098
• Publication Date: 2021-03-18T05:59:01Z
• Authors: Chao Ma; Bo Li; Jinrui Zhang; Yao Sun; Jingjing Li; Hangcheng Zhou; Jianlei Shen; Rui Gu; Jiangchao Qian; Chunhai Fan; Hongjie Zhang; Kai Liu
• Keywords: Regimen

Abstract As a typical inflammatory disease with chronic pain syndromes, rheumatoid arthritis (RA) generally requires long‐term treatment frequent injection administration at 1–2 times per day, because common medications such as interleukin1 receptor antagonist (IL1ra) have poor bioavailability and very limited half‐life residence. Here novel strategy to fabricate nanotherapeutic formulations employing genetically engineered IL1ra protein complexes, yielding ultralong‐lasting bioefficacy is developed rationally. Using rat models, it shown that these nanotherapeutics significantly improved drug regimen single subcutaneous in 14‐day therapy, suggesting their extraordinary ultralong‐acting pharmacokinetics. Specifically, the of nanoformulations are boosted level 30 h by 7 times, respectively, greater than other systems. This new thus holds great promise potently improve patient compliance RA can be adapted for therapies suffer similar drawbacks.